Allergan $AGN has recruited top cancer executive Charles Hugh-Jones, the guy who’s been leading Pfizer Oncology as CMO, to serve as the pharma giant’s new senior vice president and chief medical officer.
The move comes just 16 months after Hugh-Jones joined Pfizer’s oncology arm. Before that, he was a long timer at Sanofi in New Jersey, where he held several executive roles, ending up at chief medical officer in North America.
The move to Allergan will take Hugh-Jones back to New Jersey, as the new gig is at Allergan’s US headquarters in Madison. There, he’ll be reporting to executive vice president and chief R&D officer David Nicholson.
“Allergan is in a position to launch a number of important new products over the next couple of years. Charles will play a critical role in supporting the safe, effective and proper use of these innovative treatments among patients and their physicians,” Nicholson said in a statement.
Hugh-Jones was trained in both neuroscience and medicine at London University, becoming board certified in internal medicine and then entering the radiology fellowship program at the Royal Postgraduate Medical School in London. He practiced medicine for 8 years in the UK prior to joining the pharmaceutical industry.
In a statement, Hugh-Jones said he was excited by the breadth of Allergan’s portfolio and pipeline of therapies, which he says “holds great promise for patients in multiple therapeutic areas.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.Free Subscription